In this issue briefing, the authors model the economic burden of cardiovascular disease in Mexico—the direct costs of delivering health care services and the indirect costs from productivity losses.
Modelling the Burden of Cardiovascular Disease in Mexico
Modelling the Burden of Cardiovascular Disease in Mexico
$0.00
Cardiovascular disease (CVD) is the leading cause of death globally. Between 2016 and 2035, the number of Mexican adults with CVD will almost double, going from 1.6 million to 2.8 million. Meanwhile, the costs of health care and lost productivity will almost triple, going from US$9 billion in 2016 to US$25.6 billion by 2035. This expected increase is driven by demographic changes, mostly population growth and aging. Over time, a greater proportion of CVD cases will occur in older adults.
In Modelling the Burden of Cardiovascular Disease in Mexico, the authors look at both the direct costs of delivering health care services and their impact on the public health care system and indirect costs from productivity losses, which impact the broader society and economy. Without additional measures to mitigate the impact of population aging and modifiable risk factors, the burden of CVD in Mexico will only continue to grow.
Effective January 26, 2026, AERIC Inc./Signal49 Research discontinued use of ‘The Conference Board of Canada’ name, logo and branding, which had been used by AERIC Inc./Signal49 Research under license from The Conference Board, Inc. The Conference Board, Inc. and its licensees, which are not affiliated with Signal49 Research, own all right, title and interest in THE CONFERENCE BOARD name and trademarks in Canada and have the exclusive right to their use in Canada since January 26, 2026.
